

8th

Annual International Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation

MAY 4-6, 2000

University of Heidelberg,
Heidelberg, Germany

*Abstract Deadline Extended
to March 1, 2000*



UNIVERSITY OF CALIFORNIA
SAN DIEGO SCHOOL OF MEDICINE
UNIVERSITY OF HEIDELBERG

FINAL PROGRAM

Dear Colleague:

On behalf of the Organizing Committee, we invite you to join us for the **Eighth International Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation.**

Spawmed by the enthusiasm in the stem cell research community, we initiated this symposium in 1992. Blood-derived progenitor cells for transplantation, CD34+ separation, tumor cell purging, among others, were then novel ideas and their clinical applicability has yet to be proven. Today, some of these technologies have become clinically routine, while others have been discarded. This annual symposium, however, has remained an interactive forum to promote the exchange of novel ideas among scientists and clinicians from academic institutions as well as from the biomedical industry.

Meanwhile, the immunologic sequelae of allogeneic transplantation have been recognized as the major contributing factor for its therapeutic efficacy, whereas the long-term benefits of high-dose chemotherapy and autologous transplants have been questioned. The present trend is moving toward selective exploitation of the immunomodulatory effect of allogeneic stem cell transplantation. The goal is to establish chimerism and conditioning regimens that induce immunoblation only. Donor derived lymphocytes will be used then for ultimate cure. Early attempts have generated some encouraging clinical data.

On the threshold of a new millennium, we would like to expand our scope of activity and host this symposium alternately in San Diego and Heidelberg. Like San Diego, Heidelberg is one of the major centers in academic medicine and in biomedical research.

The topics and speakers in the preliminary program have been selected based on the suggestions and comments from participants of previous meetings and from many colleagues on both sides of the Atlantic. A special session will be devoted to abstracts selected for oral presentation, and a few abstracts will be integrated into the main sessions.

We believe that the romantic and academic ambience of Heidelberg will be conducive to the exchange of creative ideas.

We look forward to seeing you in Heidelberg.

FEES:	Before May 1, 2000	After May 1, 2000
M.D., Ph.D.	\$250	\$295

Fee includes writing materials, course syllabus, coffee breaks and the reception.

Refund Policy: A refund of the registration fee less \$50 will be allowed for cancellations prior to the conference. Notice of cancellation must be received in writing (postmarked) or by telephone by May 1, 2000. No refunds will be given after that date.

CONFERENCE LOCATION:

The conference will be held at the Communication Center of the German Cancer Research Center located on the University of Heidelberg campus.

German Cancer Research Center
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg
www.dkfz-heidelberg.de

For directions please visit our web site at <http://cme.ucsd.edu>

COURSE DIRECTORS

- Anthony D. Ho, M.D., Ph.D.**
University of Heidelberg, Germany
- Edward D. Ball, M.D.**
*University of California,
San Diego, USA*

ORGANIZING COMMITTEE

- Rainer Haas, Germany**
Ping Law, USA
- Rüdiger Hehlmann, Germany**
Jean Henslee-Downey, USA
- Dietger Niederwieser, Germany**
Peter Quesenberry, USA
- Yoichi Takaue, Japan**
Roel Willemze, Netherlands
Axel Zander, Germany

FACULTY

- Kent Anderson, M.D.**
Dana Farber Cancer Institute, USA
- Karen Antman, M.D.**
Columbia University, USA
- Franco Aversa, M.D.**
University of Perugia, Italy
- Edward Ball, M.D.**
University of California, San Diego, USA
- John Barrett, M.D.**
University Hospital, Munich, Germany
- James Berenson, M.D.**
VA Medical Center West Los Angeles, USA
- Richard Burt, M.D.**
Northwestern University, USA
- Gerhard Ehninger, M.D.**
Dresden Academy of Medicine, Germany
- Fred Falkenburg, M.D., Ph.D.**
Leiden University Medical Center, Netherlands
- Christian Gisselbrecht, M.D.**
Hospital St. Louis, France
- Eliane Gluckman, M.D.**
Hospital St. Louis, France
- John Goldman, M.D.**
Hammersmith Postgraduate Medical School, USA
- Hartmut Goldschmidt, M.D.**
University of Heidelberg, Germany
- Alois Gratwohl, M.D.**
Basel, Switzerland
- Rainer Haas, M.D.**
University of Dusseldorf, Germany
- John A. Hansen, M.D.**
Fred Hutchinson Cancer Research Center, USA
- Rüdiger Hehlmann, M.D.**
University of Heidelberg, Germany
- Jean Henslee-Downey, M.D.**
University of South Carolina, USA
- Anthony D. Ho, M.D., Ph.D.**
University of Heidelberg, Germany
- Christoph Huber, M.D.**
Istituto Scientifico San Raffaele, Italy
- Hans-Jochem Kolb, M.D.**
University Hospital, Munich, Germany
- Lothar Kanz, M.D.**
University of Tübingen, Germany
- Larry Kwak, M.D., Ph.D.**
National Institutes of Health, USA
- Martin Körbling, M.D.**
MD Anderson Cancer Center, USA
- Peter Lansdorp, M.D., Ph.D.**
Terry Fox Laboratory, Canada
- Ping Law, Ph.D.**
University of California, San Diego, USA
- Ihor Lemischka, Ph.D.**
Princeton University, USA
- Stephen McKinnon, M.D.**
University College Hospital, UK
- Shin Mineishi, M.D.**
National Cancer Center Hospital, Tokyo, Japan
- Dietger Niederwieser, M.D.**
University of Leipzig, Germany
- Bernhard Palsson, Ph.D.**
University of California, San Diego, USA
- Peter Quesenberry, M.D.**
University of Massachusetts, USA
- Ulrich Wilhelm Schaefer, M.D.**
University of Essen, Germany
- Norbert Schmitz, M.D.**
University of Kiel, Germany
- Akihiro Shimosaka, Ph.D.**
Kirin Brewery Company, Japan
- Megan Sykes, M.D.**
Massachusetts General Hospital, USA
- Yoichi Takaue, M.D.**
University of Minnesota, USA
- Alan Tyndall, M.D.**
Basel, Switzerland
- Catherine Verfaillie, M.D.**
University of Nebraska Medical Center, USA
- Douglas Williams, Ph.D.**
Immunex Corporation, USA
- Roel Willemze, M.D.**
University of Leiden Medical Center, Netherlands
- Axel Zander, M.D.**
University Hospital Eppendorf, Germany
- Esmail Zanjani, Ph.D.**
VA Medical Center, Reno, USA

Recent Advances in Hematopoietic Stem Cell Transplantation

University of Heidelberg, Heidelberg, Germany

PROGRAM

THURSDAY, MAY 4, 2000

7:00 AM Registration

BASIC AND APPLIED RESEARCH

Chairperson: Peter Quesenberry

8:00 Comparative Evaluation of the In Vivo Engraftment Potential of Human Cord Blood, Bone Marrow, and Blood HSC
Esmail Zanjani, Ph.D.

8:30 Inhibition of Vasculogenesis by Soluble TEK Receptor
Douglas Williams, Ph.D.

9:00 Novel Purging Technology: High Speed Laser Ablation
Bernhard Palsson, Ph.D.

9:30 KRN 7000 and Dendritic Cells
Akihiro Shimosaka, Ph.D.

10:00 Coffee Break

STEM CELL BIOLOGY

Chairperson: Ping Law, Ph.D.

10:30 The Molecular Biology of Hematopoietic Stem Cells and Their Microenvironment
Ihor Lemischka, Ph.D.

11:00 Telomeres and Stem Cells: An Update
Peter Lanscorp, M.D., Ph.D.

11:30 The Plastic Phenotype of the Hematopoietic Stem Cell and Non-Toxic Allochimerism
Peter Quesenberry, M.D.

12:00 Homing and Self-Renewal of Hematopoietic Stem Cells
Anthony D. Ho, M.D., Ph.D.

12:30 PM Lunch on Own

GRAFT/HOST MANIPULATION

Chairperson: Rainer Haas, M.D.

1:30 Multiple Myeloma: Manipulating the Graft to Both Reduce Tumor Burden and Increase Anti-Tumor Effect
James Berenson, M.D.

2:00 Use of Monoclonal Antibodies in HSCT for Leukemia
Edward Ball, M.D.

2:30 Graft Manipulation in Stem Cell Transplantation Across the HLA-Barriers
Franco Aversa, M.D.

3:00 Adoptive Immunotherapy of Relapsed Leukemia after Transplantation with ExVivo Expanded Cytotoxic T-Cells
Fred Falkenburg, M.D., Ph.D.

3:30 Break

IMMUNE RECONSTITUTION/DLI

Chairperson: Edward Ball, M.D.

4:00 Immune Reconstitution Following Donor Lymphocyte Infusions for Relapsed CML
Stephen McKinnon, M.D.

4:30 Adoptive Immunotherapy in Chimeras
Hans-Jochem Kolb, M.D.

5:00 Immune Reconstitution after Allogeneic Stem Cell Transplants
John Barrett, M.D.

5:30 Immune Reconstitution after Transplantation of Haplo-Identical CD34+ Peripheral Stem Cell in Children
Paul Schlegel, M.D.

6:00 Poster Session

7:30 PM Welcome Reception

FRIDAY, MAY 5, 2000

CRITICAL ISSUES IN ALLOGENEIC TRANSPLANTATIONS

Chairperson: Roel Willemze, M.D.

8:00 AM Allogeneic Transplants for CML – When and How?
Alois Gratwohl, M.D.

8:30 Allografting with Peripheral Blood Stem Cells - A Single-Center Experience
Ulrich Wilhelm Schaefer, M.D.

9:00 Critical Issues and New Developments in Allogeneic Transplantation
Norbert Schmitz, M.D.

9:30 Matched and Mismatched Unrelated Donor Stem Cell Transplantation in Leukemia
Axel Zander, M.D.

10:00 Break

CRITICAL ISSUES IN AUTOLOGOUS TRANSPLANTATION

Chairperson: Axel Zander, M.D.

- 10:30 **Critical Issues in Autologous Transplantation in Lymphoma**
Christian Gisselbrecht, M.D.
- 11:00 **New Perspectives in the Treatment of Non-Hodgkin-Lymphomas**
Rainer Haas, M.D.
- 11:30 **Autografting in Chronic Myelogenous Leukemia - Autografting, Gene Therapy and Signal Transduction Inhibitors**
Catherine Verfaillie, M.D.
- 12:00 **Collection of Blood Stem Cells from Patients Undergoing Treatment with Interferon Alpha**
John Goldman, M.D.

12:30 PM **Lunch On Own**

CONTROVERSIES IN STEM CELL TRANSPLANTS

Chairperson: Anthony D. Ho, M.D., Ph.D.

- 1:30 **Strategies for Improving the Outcome of Hematopoietic Stem Cell Transplantation for Multiple Myeloma**
Kent Anderson, M.D.
- 1:50 **High-Dose Therapy in Multiple Myeloma**
Hartmut Goldschmidt, M.D.
- 2:10 **Evidences for Superiority of Transplantation in Adult AML**
Roel Willemze, M.D.
- 2:30 **Controversies in the Treatment of Chronic Myeloid Leukemia**
Rüdiger Hehlmann, M.D.
- 2:50 **The Role of High Dose Chemotherapy in Breast Cancer**
Karen Antman, M.D.
- 3:10 **Hematopoietic Stem Cell Transplants in Autoimmune Disease - Which Patients and When?**
Alan Tyndall, M.D.
- 3:30 **Stem Cell Transplants - Pros and Cons of Stem Cell Transplantation for Autoimmune Disease**
Richard Burt, M.D.
- 3:50 **Panel Discussion**
- 4:30 **Break**

ALTERNATIVE DONORS

Chairperson: Jean Henslee-Downey, M.D.

- 5:00 **Use of Unrelated Mismatched Cord Blood Transplant in Children**
Eliane Gluckman, M.D.
- 5:30 **Unrelated Donor Transplants**
John A. Hansen, M.D.
- 6:00 **Haplo-Identical Transplantation**
Jean Henslee-Downey, M.D.
- 6:30 **Allogeneic Transplantation with CD34+ Blood Cells**
Yoichi Takaue, M.D.
- 7:00 PM **Adjourn**

SATURDAY, MAY 6, 2000

ALLOGRAFTING WITH IMMUNOABLATION

Chairperson: Rudiger Hehlmann, M.D.

- 8:00 AM **Allografting after Reduced Conditioning Protocols**
Gerhard Ehninger, M.D.
- 8:30 **Hematological and Immunological Reconstitution in Non-Myeloablative Stem Cell Transplantation**
Shin Mineishi, M.D.
- 9:00 **Induction of Chimerization for the Treatment of Malignancies Using Unrelated Donors**
Dieter Niederwieser, M.D.
- 9:30 **Immunomodulation of Stem Cell Allografts and Donor Lymphocytes: The Role of Dendritic Cells and other Lymphoid Subsets**
Martin Körbling, M.D.
- 10:00 **Coffee Break**

GENE MANIPULATION

Chairperson: Rainer Haas, M.D.

- 10:30 **Generation of Dendritic Cells for Use in Specific Immunotherapy**
Lothar Kanz, M.D.
- 11:00 **Concepts for Development of Allogeneic Stem Cell Transplantation**
Christoph Huber, M.D.
- 11:30 **Vaccination Against Hematologic Malignancy Peri-Transplantation**
Larry Kwak, M.D., Ph.D.
- 12:00 **Mixed Allogeneic Chimerism Induced with Non-Myeloablative Conditioning: Experience in Animals and Man**
Megan Sykes, M.D.
- 12:30 PM **Final Adjournment**